Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective …

Methods PEMMELA was a prospective single-center, single-arm, open-label, investigator-
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus …

Background Pleural mesothelioma usually presents at an advanced, incurable stage.
Chemotherapy with platinum–pemetrexed is a standard treatment. We hypothesised that the …

Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

Introduction Malignant pleural mesothelioma (MPM) is an aggressive malignancy that affects
older adults with frequent comorbidities, making real-world treatment decisions challenging …

Importance Some recently proposed frontline therapies for malignant pleural mesothelioma
(MPM) are very costly, yet their impact on quality of life and overall survival of these patients …

In inoperable pleural mesothelioma, pemetrexed+ cisplatin as first line is considered the
standard of care, but novel treatments have been recently proposed. Our objective was to …

Background Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with poor
prognosis and limited treatment options after progression on platinum-containing …

Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …

Background Malignant pleural mesothelioma (MPM) remains a challenging disease to
manage. In the past few decades, extrapleural pneumonectomy (EPP), pemetrexed-based …